If you’re looking to stay informed about the latest developments in health and medicine, STAT’s free newsletter Morning Rounds is a must-read. Sign up now to get your daily dose of insightful news and updates.
Good morning! Lev Facher here, stepping in for Theresa. Let’s dive into today’s top stories.
### New Analysis Suggests Study on GLP-1s and Kids Was Potentially Shaped by Industry
The American Academy of Pediatrics’ recent guidelines on treating obesity in children sparked controversy for its pro-medication stance on GLP-1s. However, a recent analysis revealed that a significant portion of the committee members had undisclosed financial ties to pharmaceutical companies involved in developing these medications. This raises concerns about potential conflicts of interest in the guideline development process. To learn more, check out Isabella Cueto’s detailed report.
### A Long Covid Drug Fails a Clinical Trial, But May Get Another Shot
Hope was on the horizon for long Covid patients with the development of a new drug candidate, BC 007. However, after a failed clinical trial and financial setbacks, the future of this potential treatment remains uncertain. Betsy Ladyzhets’ in-depth coverage sheds light on the challenges of developing therapies for long Covid and the impact of clinical trial outcomes on patients.
### Study Traces Decline in NIH-Funded Basic Research, Even Before Trump Cuts
A recent analysis by former NIH deputy director Michael Lauer revealed a decline in NIH-funded research output, raising concerns about the impact of budget cuts on scientific progress. The current political climate presents an opportunity to reevaluate and strengthen research efforts. Anil Oza’s interview with Lauer explores the implications of this research decline and potential pathways for improvement.
### Biotech Eyes a New Class of Narcolepsy Drugs
Biotech companies are racing to develop innovative narcolepsy treatments known as orexin receptor agonists, with the potential to revolutionize sleep disorder therapy. Elaine Chen’s in-depth report highlights the promising developments in this field and the transformative impact these medications could have on narcolepsy and related conditions.
### ICE Refusing Medical Care for Disabled Detainees, Advocacy Group Says
Disability Rights California’s recent report sheds light on the inadequate medical care provided to disabled detainees at ICE processing centers, raising alarming concerns about human rights violations. The report underscores the urgent need for improved healthcare access and support for vulnerable populations in detention facilities.
### Just Move: For People with Diabetes, Even a Little Activity Every Week is Tied to Better Health
A new study published in the Annals of Internal Medicine reveals the significant health benefits of physical activity for individuals with diabetes, emphasizing the importance of regular exercise in reducing mortality and cardiovascular risk. Elizabeth Cooney’s coverage explores the positive impact of even minimal physical activity on overall well-being for individuals with diabetes.
### What We’re Reading
– Sarepta Therapeutics halts Duchenne gene therapy shipments in a surprising move, as reported by STAT.
– The New York Times delves into the concerns of disabled Americans regarding potential Medicaid cuts.
– The Congressional Budget Office predicts 10 million individuals will lose health insurance under Trump’s tax cut law, according to STAT’s coverage.
– The New Yorker shares a compelling story of a woman’s journey with schizophrenia and recovery.
– Opinion piece on the implications of medical debt’s return to credit reports for cancer patients, courtesy of STAT.
Stay informed and engaged with the latest news and insights in health and medicine. Sign up for Morning Rounds to receive your daily briefing on the most pressing issues in the field.
